Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor

K. H. Chen, M. Wada, K. G. Pinz, H. Liu, K. W. Lin, A. Jares, A. E. Firor, X. Shuai, Huda Shafic Salman, M. Golightly, F. Lan, L. Senzel, E. L. Leung, X. Jiang, Y. Ma

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The outlook for T-cell malignancies remain poor due to the lack of effective therapeutic options. Chimeric antigen receptor (CAR) immunotherapy has recently shown promise in clinical trials for B-cell malignancies, however, designing CARs for T-cell based disease remain a challenge due to the shared surface antigen pool between normal and malignant T-cells. Normal T-cells express CD5 but NK (natural killer) cells do not, positioning NK cells as attractive cytotoxicity cells for CD5CAR design. Additionally, CD5 is highly expressed in T-cell acute lymphoblastic leukemia (T-ALL) and peripheral T-cell lymphomas (PTCLs). Here, we report a robust anti-CD5 CAR (CD5CAR) transduced into a human NK cell line NK-92 that can undergo stable expansion ex vivo. We found that CD5CAR NK-92 cells possessed consistent, specific, and potent anti-tumor activity against a variety of T-cell leukemia and lymphoma cell lines as well as primary tumor cells. Furthermore, we were able to demonstrate significant inhibition and control of disease progression in xenograft mouse models of T-ALL. The data suggest that CAR redirected targeting for T-cell malignancies using NK cells may be a viable method for new and complementary therapeutic approaches that could improve the current outcome for patients.

Original languageEnglish (US)
Pages (from-to)2151-2160
Number of pages10
JournalLeukemia
Volume31
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

CD5 Antigens
Antigen Receptors
Natural Killer Cells
T-Lymphocytes
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Neoplasms
Peripheral T-Cell Lymphoma
T-Cell Leukemia
Cell Line
T-Cell Lymphoma
Surface Antigens
Heterografts
Immunotherapy
Disease Progression
B-Lymphocytes
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Chen, K. H., Wada, M., Pinz, K. G., Liu, H., Lin, K. W., Jares, A., ... Ma, Y. (2017). Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia, 31(10), 2151-2160. https://doi.org/10.1038/leu.2017.8

Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. / Chen, K. H.; Wada, M.; Pinz, K. G.; Liu, H.; Lin, K. W.; Jares, A.; Firor, A. E.; Shuai, X.; Salman, Huda Shafic; Golightly, M.; Lan, F.; Senzel, L.; Leung, E. L.; Jiang, X.; Ma, Y.

In: Leukemia, Vol. 31, No. 10, 01.10.2017, p. 2151-2160.

Research output: Contribution to journalArticle

Chen, KH, Wada, M, Pinz, KG, Liu, H, Lin, KW, Jares, A, Firor, AE, Shuai, X, Salman, HS, Golightly, M, Lan, F, Senzel, L, Leung, EL, Jiang, X & Ma, Y 2017, 'Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor', Leukemia, vol. 31, no. 10, pp. 2151-2160. https://doi.org/10.1038/leu.2017.8
Chen, K. H. ; Wada, M. ; Pinz, K. G. ; Liu, H. ; Lin, K. W. ; Jares, A. ; Firor, A. E. ; Shuai, X. ; Salman, Huda Shafic ; Golightly, M. ; Lan, F. ; Senzel, L. ; Leung, E. L. ; Jiang, X. ; Ma, Y. / Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. In: Leukemia. 2017 ; Vol. 31, No. 10. pp. 2151-2160.
@article{45ce1feebcdd490d93c86d647a15dab3,
title = "Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor",
abstract = "The outlook for T-cell malignancies remain poor due to the lack of effective therapeutic options. Chimeric antigen receptor (CAR) immunotherapy has recently shown promise in clinical trials for B-cell malignancies, however, designing CARs for T-cell based disease remain a challenge due to the shared surface antigen pool between normal and malignant T-cells. Normal T-cells express CD5 but NK (natural killer) cells do not, positioning NK cells as attractive cytotoxicity cells for CD5CAR design. Additionally, CD5 is highly expressed in T-cell acute lymphoblastic leukemia (T-ALL) and peripheral T-cell lymphomas (PTCLs). Here, we report a robust anti-CD5 CAR (CD5CAR) transduced into a human NK cell line NK-92 that can undergo stable expansion ex vivo. We found that CD5CAR NK-92 cells possessed consistent, specific, and potent anti-tumor activity against a variety of T-cell leukemia and lymphoma cell lines as well as primary tumor cells. Furthermore, we were able to demonstrate significant inhibition and control of disease progression in xenograft mouse models of T-ALL. The data suggest that CAR redirected targeting for T-cell malignancies using NK cells may be a viable method for new and complementary therapeutic approaches that could improve the current outcome for patients.",
author = "Chen, {K. H.} and M. Wada and Pinz, {K. G.} and H. Liu and Lin, {K. W.} and A. Jares and Firor, {A. E.} and X. Shuai and Salman, {Huda Shafic} and M. Golightly and F. Lan and L. Senzel and Leung, {E. L.} and X. Jiang and Y. Ma",
year = "2017",
month = "10",
day = "1",
doi = "10.1038/leu.2017.8",
language = "English (US)",
volume = "31",
pages = "2151--2160",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor

AU - Chen, K. H.

AU - Wada, M.

AU - Pinz, K. G.

AU - Liu, H.

AU - Lin, K. W.

AU - Jares, A.

AU - Firor, A. E.

AU - Shuai, X.

AU - Salman, Huda Shafic

AU - Golightly, M.

AU - Lan, F.

AU - Senzel, L.

AU - Leung, E. L.

AU - Jiang, X.

AU - Ma, Y.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - The outlook for T-cell malignancies remain poor due to the lack of effective therapeutic options. Chimeric antigen receptor (CAR) immunotherapy has recently shown promise in clinical trials for B-cell malignancies, however, designing CARs for T-cell based disease remain a challenge due to the shared surface antigen pool between normal and malignant T-cells. Normal T-cells express CD5 but NK (natural killer) cells do not, positioning NK cells as attractive cytotoxicity cells for CD5CAR design. Additionally, CD5 is highly expressed in T-cell acute lymphoblastic leukemia (T-ALL) and peripheral T-cell lymphomas (PTCLs). Here, we report a robust anti-CD5 CAR (CD5CAR) transduced into a human NK cell line NK-92 that can undergo stable expansion ex vivo. We found that CD5CAR NK-92 cells possessed consistent, specific, and potent anti-tumor activity against a variety of T-cell leukemia and lymphoma cell lines as well as primary tumor cells. Furthermore, we were able to demonstrate significant inhibition and control of disease progression in xenograft mouse models of T-ALL. The data suggest that CAR redirected targeting for T-cell malignancies using NK cells may be a viable method for new and complementary therapeutic approaches that could improve the current outcome for patients.

AB - The outlook for T-cell malignancies remain poor due to the lack of effective therapeutic options. Chimeric antigen receptor (CAR) immunotherapy has recently shown promise in clinical trials for B-cell malignancies, however, designing CARs for T-cell based disease remain a challenge due to the shared surface antigen pool between normal and malignant T-cells. Normal T-cells express CD5 but NK (natural killer) cells do not, positioning NK cells as attractive cytotoxicity cells for CD5CAR design. Additionally, CD5 is highly expressed in T-cell acute lymphoblastic leukemia (T-ALL) and peripheral T-cell lymphomas (PTCLs). Here, we report a robust anti-CD5 CAR (CD5CAR) transduced into a human NK cell line NK-92 that can undergo stable expansion ex vivo. We found that CD5CAR NK-92 cells possessed consistent, specific, and potent anti-tumor activity against a variety of T-cell leukemia and lymphoma cell lines as well as primary tumor cells. Furthermore, we were able to demonstrate significant inhibition and control of disease progression in xenograft mouse models of T-ALL. The data suggest that CAR redirected targeting for T-cell malignancies using NK cells may be a viable method for new and complementary therapeutic approaches that could improve the current outcome for patients.

UR - http://www.scopus.com/inward/record.url?scp=85019981328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019981328&partnerID=8YFLogxK

U2 - 10.1038/leu.2017.8

DO - 10.1038/leu.2017.8

M3 - Article

VL - 31

SP - 2151

EP - 2160

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 10

ER -